With the aging HIV population, it is important to understand how inflammation and age-related comorbidities will affect treatment options in this population moving forward. This was the topic of Tuesday’s...
With the aging HIV population, it is important to understand how inflammation and age-related comorbidities will affect treatment options in this population moving forward. This was the topic of Tuesday’s...
Results of a new study presented at CROI 2019, found the efficacy and safety of F/TAF versus F/TDF for PrEP in MSM and transgender women who are at high risk of HIV acquisition.
Results of a new study presented at CROI 2019, found the efficacy and safety of F/TAF versus F/TDF for PrEP in MSM and transgender women who are at high risk of HIV acquisition.
Results of a new study presented at CROI 2019, found the efficacy and safety of F/TAF versus F/TDF for PrEP in MSM and transgender women who are at high risk of HIV acquisition.
Results of a new study presented at CROI 2019, found the efficacy and safety of F/TAF versus F/TDF for PrEP in MSM and transgender women who are at high risk of HIV acquisition.
In this plenary session, Alexandra M. Oster, from the CDC, discusses molecular detection of HIV clusters, how the United States has used that data, and how researchers have responded to these clusters.
...
In this plenary session, Alexandra M. Oster, from the CDC, discusses molecular detection of HIV clusters, how the United States has used that data, and how researchers have responded to these clusters.
...
In this plenary session, Alexandra M. Oster, from the CDC, discusses molecular detection of HIV clusters, how the United States has used that data, and how researchers have responded to these clusters.
...
In this plenary session, Alexandra M. Oster, from the CDC, discusses molecular detection of HIV clusters, how the United States has used that data, and how researchers have responded to these clusters.
...
